Minimal residual disease, long-term outcome, and IKZF1deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study

Patients with Down syndrome and acute lymphocytic leukaemia are at an increased risk of treatment-related mortality and relapse, which is influenced by unfavourable genetic aberrations (eg, IKZF1deletion). We aimed to investigate the potential underlying effect of Down syndrome versus the effects of adverse cancer genetics on clinical outcome.